FDA Brief

Company record

Summit Research Peptides

1 FDA warning letter since 2023 and 0 recalls in the last 12 months.

Get an email the day FDA posts anything new about Summit Research Peptides.

Warning letters

  1. Summit Research Peptides

    FDA warned Summit Research Peptides for selling unapproved semaglutide, retatrutide, cagrilintide, tirzepatide, and mazdutide with drug claims.

    High risk